The past 5 years have seen significant developments in the treatment of colorectal cancer (CRC). New chemotherapy agents with activity in CRC have demonstrated an improvement in survival for patients with advanced CRC. Studies now are focusing on combinations and sequences of chemotherapy agents to prolong survival in secondand even third-line therapies. Oral agents have been developed and are being studied in combination chemotherapy regimens. Development of oral combinations should maintain a survival advantage with the added benefit of convenience for the patient. Drugs designed to act on specific cellular protein targets have also shown activity and are being explored further. Researchers continue to pursue immunotherapy and vaccine therapy. Studies are now focusing on how best to use the available agents. These new agents and new combinations of agents and of approaches have led and should continue to lead to improved outcomes in the treatment of patients with CRC. (JNCCN 2003;1:125-136) More than 130,000 people per year in the United States will be diagnosed with colorectal cancer (CRC).
More than 130,000 people per year in the United States will be diagnosed with colorectal cancer (CRC). 1 More than one third of these patients will have metastatic disease at the time of presentation and will benefit from therapy to improve survival and quality of life. Of the remaining two thirds, many will be candidates for adjuvant therapy to prevent recurrence. Over the past 5 years, 2 additional chemotherapy agents with activity in CRC have been identified and approved for use. Targeted therapies such as monoclonal antibodies, small peptides, vaccine therapies, and antiangiogenic agents are in development. This article discusses recent studies evaluating some of the most promising new agents in the treatment of CRC.
5-Fluorouracil
Of existing agents, 5-fluorouracil (5-FU) has remained the cornerstone of therapy for CRC for more than 30 years. Multiple studies have demonstrated equivalent overall survival and a superior toxicity profile for 5-FU delivered on an infusion schedule instead of a bolus schedule. [2] [3] [4] Despite these results, practitioners and patients have been less accepting of infusion schedules because they require the use of indwelling catheters. Indwelling catheters are perceived to be cumbersome and carry a significant risk of infection. A French phase III study compared a bimonthly schedule of leucovorin, bolus 5-FU, and infusion 5-FU (LV5FU2) with the North Central Cancer Treatment Group (NCCTG)/Mayo regimen of bolus 5-FU and leucovorin. 5 The investigators demonstrated an improved response rate (32.6% vs 14.5%; P = .0004), progression-free survival (27.6 vs 22.0 weeks; P= .0012), and a more favorable toxicity profile (grade 3 or grade 4 toxicity of 11.1% compared with 22.9%) with the infusion schedule, with equivalent overall survival. The regimen used in this study consisted of leucovorin at a dose of 200 mg/m 2 given over 2 hours, followed by a bolus of 5-FU at 400 mg/m 2 and a continuous infusion of 5-FU at a dose of 600 mg/m 2 over 22 hours for 2 consecutive days every 2 weeks. This schedule and variations of it have been further developed in combination chemotherapy regimens.
Irinotecan
Two randomized studies reported in 1998 established the role of irinotecan (CPT-11) as a second-line therapy for the treatment of advanced CRC after progression on a 5-FU-based regimen. Cunningham et al 6 examined the benefit of irinotecan compared with best supportive care after progression on 2 or fewer 5-FU-based regimens for advanced disease. They found an improvement in survival at 12 months (36.2% vs 13.8%; P= .0001) and a clinical benefit as evidenced by a decrease in weight loss, performance status deterioration, and pain, favoring the irinotecan intervention. Rougier et al 7 compared irinotecan with an infusion schedule of 5-FU as second-line therapy for patients who had progressed on a bolus regimen of 5-FU. Survival at 12 months was significantly better for patients receiving irinotecan (45% vs 32%; P = .035), and clinical benefits were also seen.
In 2 independent studies, the combination of 5-FU, leucovorin, and irinotecan has been shown to improve survival over 5-FU and leucovorin alone as first-line therapy for advanced CRC (Table 1) . 8, 9 The bolus schedule described by Saltz et al 8 (irinotecan, 5-FU, leucovorin [IFL] ) and the bolus and infusion schedule described by Douillard et al 9 (CPT-11/ LV5FU2) were approved by the Food and Drug Administration (FDA) in March 2000 as first-line therapy for advanced CRC and have become a standard of care. These combinations have been incorporated into many recent large, randomized studies as the standard arm for the treatment of advanced CRC and as the comparative arm for adjuvant therapy for resected localized disease.
Oxaliplatin
The platinum agent oxaliplatin has been used throughout Europe, Central and South America, and Asia and has recently been approved in the United States. Oxaliplatin is a diaminocyclohexane platinum with a different preclinical activity profile than cisplatin. It also has a distinct toxicity profile, different from other platinum agents. There is no renal toxicity, minimal hematotoxicity, and both a reversible acute, cold-related dysesthesia and a doselimiting cumulative peripheral sensory neuropathy. Phase II single-agent studies of oxaliplatin in patients with 5-FU-refractory disease and in previously untreated patients demonstrated objective response rates comparable to those with 5-FU single-agent therapy. [10] [11] [12] [13] In vitro and in vivo, oxaliplatin has shown additive or synergistic cytotoxic properties with many agents, including fluoropyrimidines and topoisomerase I inhibitors.
14 These combinations are being explored further.
Three phase III studies have demonstrated a superior response rate for a combination of oxaliplatin, 5-FU, and leucovorin over combined 5-FU and leucovorin without oxaliplatin as first-line therapy for advanced CRC. However, these studies did not have enough statistical power to prove a statistically significant survival benefit. Giacchetti et al 15 administered a chronomodulated regimen of 5-FU and leucovorin with or without oxaliplatin and showed an improvement in response rate from 12% to 34% (P < .0001), with no difference in overall survival. de Gramont et al 16 randomized 420 patients to receive a bolus and infusion schedule of 5-FU and leucovorin with or without oxaliplatin. An improved response rate (51% vs 22%; P = .0001) was attained with the addition of oxaliplatin. Median overall survival was prolonged in the group receiving oxaliplatin; however, the difference was not statistically significant (16.2 vs 14.7 months; P = .12). Both of these studies allowed crossover to the oxaliplatin-containing regimen if progression was documented on the 5-FU and leucovorin arms. 
National Cancer Institute Gastrointestinal Intergroup Trial
To establish the best first line regimen in advanced CRC, the United States National Cancer Institute Gastrointestinal Intergroup designed a 6-arm study, coordinated by NCCTG, comparing various combinations used throughout the United States and Europe of 5-FU, leucovorin, irinotecan, and oxaliplatin. 20 After irinotecan was accepted as standard first-line therapy and real-time toxicity monitoring identified unacceptable toxicity in 2 of the arms, the protocol was amended to a 3-arm study. The regimens tested included the 5-FU and irinotecan bolus combination regimen described by Saltz et al 8 (IFL), the 5-FU and oxaliplatin bolus and infusion regimen described by de Gramont et al 18 (FOLFOX4) , and an irinotecan and oxaliplatin combination. 21 In April of 2001, real-time toxicity monitoring identified an unexpectedly high death rate in the IFL combination, which was considered the standard arm, and the study was suspended. A panel was assigned to review the management and cause of death of each patient and to identify a risk profile, which might allow for early identification of patients at high risk for toxicity. 22 The panel reviewed the 13 deaths in the standard arm and 5 deaths in each of the other 2 arms. No clear high-risk profile was identified, but concurrent or overlapping toxicities were characterized into 2 syndromes: A gastrointestinal syndrome consisted of diarrhea, nausea, vomiting, anorexia, and abdominal cramping often associated with dehydration, neutropenia, fever, and electrolyte abnormalities; and a vascular syndrome was identified as an acute, fatal myocardial infarction, pulmonary embolus, or cerebrovascular accident not necessarily associated with other treatment-related toxicities or underlying conditions. The Intergroup study was reopened with modifications to the doses and management of the IFL arm, including initiation of fluoroquinolone antibiotics for neutropenia or diarrhea with fever (Table 2 ).
Grothey et al
17 compared an infusion schedule of 5-FU, leucovorin, and oxaliplatin to the NC-CTG/Mayo bolus regimen of 5-FU and leucovorin and also found an improved response rate (50.9% compared with 23.3%; P = .0001) and a trend toward improved overall survival (20.4 vs 16.7 months; P value not reported) for the oxaliplatin-containing regimen. Although these studies demonstrated an improved response rate of the oxaliplatin combination, they were not designed to demonstrate a statistically significant improvement in survival. Improvement in survival is a regulatory standard for approval of first-line therapy for CRC by the FDA.
Oxaliplatin has also shown activity in 5-FU-refractory metastatic CRC and has been evaluated as second-line therapy after progression on 5-FU and leucovorin. Forty-six patients whose disease had progressed on 5-FU and leucovorin were treated with the bolus and infusion schedule of 5-FU, leucovorin, and oxaliplatin. 18 Of 46 patients, 22 had disease progression on the same dose and schedule of 5-FU and leucovorin alone. An overall response rate of 46% was seen with the bolus and infusion schedule of 5-FU and leucovorin with oxaliplatin. The 22 patients who had previous disease progression on the same dose and schedule of 5-FU and leucovorin had a comparable response rate of 45% as a result of the addition of oxaliplatin.
A multicenter, randomized controlled study comparing the effectiveness and safety of oxaliplatin alone, LV5FU2, or oxaliplatin with LV5FU2 (FOL-FOX4) after progression on IFL has recently been reported. 19 Accrual to the study is complete, with 821 patients enrolled. Response data for 459 patients have been evaluated in a planned interim analysis, but survival data for all 821 patients are not yet available. Response rate is improved for patients receiving FOLFOX4 after progression on IFL, as compared with LV5FU2 or oxaliplatin alone (9% vs 0% vs 2%; P value for FOLFOX4 vs LV5FU2 = .0002). Time to disease progression is prolonged for patients receiving FOLFOX4 as compared with those receiving LV5FU2 or oxaliplatin (4.6 vs 2.7 vs 1.6 months). Based on the response rate and time to tumor progression, the FDA approved oxaliplatin in combination with infusion 5-FU and leucovorin for the treatment of IFL-refractory CRC. 19 This approval is despite the lack of mature controlled trials that demonstrate a clinical benefit such as improved disEarly results of the Intergroup study, before the suspension of the study and subsequent reduction in doses of the IFL regimen, were recently presented. 20 Approximately 260 subjects had been randomized to each of the 3 arms. A significant difference has been achieved in the FOLFOX4 regimen as compared with the IFL regimen (Table 3) . A superior response rate (38% vs 29%; P < .05), time to disease progression (8.8 vs 6.9 months; P = .0009) (Fig. 1) , and overall survival (18.6 vs 14.1 months; P = .002) (Fig. 2) was demonstrated for the FOLFOX4 regimen. There were 3 significant differences in the context of this study, any one of which may account for survival differences. First, the IFL regimen uses bolus 5-FU, whereas the FOLFOX4 regimen uses a combination of bolus and infusion 5-FU. Second, after disease progression on FOLFOX4, 52% of patients were given irinotecan, whereas only 17% of patients whose disease progressed on IFL received an oxaliplatin regimen after progression. Finally, sequence dependency may play a role in the durability of response.
The cross-resistance profile of 5-FU and leucovorin given in a bolus and infusion schedule with irinotecan or oxaliplatin was examined in a phase III study involving 226 patients. 23 Patients were randomized to either the irinotecan-or oxaliplatin-containing combination regimen and then crossed over at the time of progression. No difference in overall survival was demonstrated in this study, regardless of the sequence of therapy (20.4 vs to 21.5 months; P = .9). Although the addition of infusion 5-FU to oxaliplatin clearly enhances efficacy in a synergistic fashion, this benefit has not been proven for irinotecan. Patients with advanced CRC who receive 5-FU with oxaliplatin as first-line therapy probably do not receive any benefit from the addition of 5-FU to irinotecan as second-line therapy; however, oxaliplatin should always be given with 5-FU to enhance activity regardless of previous 5-FU exposure. At this time, the most efficacious and durable combination and sequence of agents is still undetermined. Any of these combinations would be a reasonable approach for the patient with advanced CRC (Table 4) . It is clear, however, through this study and others that the availability of all 3 active agents improves survival in advanced CRC. In fact, when all 3 drugs are available, overall survival of up to 20 months is consistently achieved. 15, 17, 23 e. Oral fluoroquinelone treatment should be initiated in patients who develop an absolute neutrophil count less than 500/µl, even in the absence of fever or diarrhea, or a fever that occurs in the setting of diarrhea, even without neutropenia.
3. Appropriate antibiotics should be initiated in any patient hospitalized with prolonged diarrhea, regardless of neutrophil count, and should be continued until resolution of diarrhea.
4. Physicians should consider grade and duration of toxicity, need and use of supportive care, impact on performance status, and interval since resolution of toxicity in the decision to administer a scheduled dose of IFL. 
Oral Chemotherapeutic Agents
Efforts to simplify therapy and improve patients' and practitioners' acceptance of regimens have focused on the development of oral agents. Oral agents provide sustained exposure to drug, allow patients to avoid the technical barrier of intravenous administration, and provide flexibility and convenience for patients; however, the development of effective oral agents has been hampered by the erratic bioavailability of oral 5-FU. Techniques to circumvent this problem have relied on the production of prodrugs and the inhibition of inactivating enzymes (Fig. 3) . Two phase III studies have compared the use of the oral fluoropyrimidine prodrug capecitabine to the NCCTG/Mayo bolus regimen of 5-FU and leucovorin as first-line therapy in metastatic CRC. 24, 25 The study conducted by Hoff et al 24 demonstrated an improved response rate with capecitabine (24.8% vs 15.5%; P = .005) without a significant improvement in overall surtoxicity. Although both studies demonstrated response rates comparable to intravenous 5-FU and oxaliplatin combinations, the toxicity encountered underscores the importance of administering these combinations in the setting of clinical trials. Whether capecitabine combinations maintain the same survival advantage as seen with intravenous 5-FU (particularly infusion 5-FU) remains a research question.
Other oral agents have been or are undergoing evaluation. Uracil is a competitive substrate for dihydropyrimidine dehydrogenase, the inactivating enzyme of 5-FU. Coadministration of uracil or its analogue eniluracil with a fluoropyrimidine compound will result in increased plasma and tumor concentrations of 5-FU by slowing its intracellular breakdown. Two phase III studies have compared the combination of oral eniluracil and oral 5-FU with intravenous 5-FU and leucovorin on the NCCTG/Mayo schedule.
28,29 Both studies demonstrated an inferior outcome with the oral regimen. UFT is another oral compound, which is a combination of the 5-FU prodrug tegafur (also known as ftorafur) and uracil in a molar ratio of 1:4. A large phase III study compared this compound with the NCCTG/Mayo regimen of intravenous 5-FU and leucovorin. 30 Despite a comparable response rate (11.7% vs 14.5%; P = .232), overall survival (12.4 vs 13.4 months; P = .630), and superior toxicity profile, the FDA withheld approval of UFT in a controversial decision.
31 S-1 is another oral fluoropyrimidine, which adds 2 biomodulators to enhance efficacy and minimize toxicity. Tegafur is combined with 5-chloro-2,4-dihydroxypyridine, a potent dihydropyrimidine dehydrogenase inhibitor and potassium oxonate, a nonspecific gut phosphoribosyl transferase inhibitor.
Inhibition of phosphoribosyl transferase should lower gastrointestinal toxicity. A phase II study of S-1 in advanced CRC resulted in a response rate of 35% for 62 patients without previous therapy for metastatic disease.
32 S-1 is currently approved and available in Japan for the treatment of gastric cancer. Oral formulations of irinotecan are currently under investigation, including early phase trials in combination with capecitabine.
Immunotherapy
Immunotherapy has been studied as an attractive approach to eradicating microscopic disease after surgical resection. Nonspecific immunotherapy as an adjuvant treatment for stage II or III colon cancer using intradermal Bacillus Calmette-Guérin (BCG) was evaluated in the National Surgical Adjuvant Breast and Bowel Project (NSABP-C-01). 33 The BCGtreated group demonstrated a slight but not statistically significant improvement in survival. The Eastern Cooperative Oncology Group (ECOG) studied the benefit of active specific immunotherapy with an autologous tumor cell-BCG vaccine. 35 prompting interest in its activity in micrometastatic disease. In a study involving 189 patients with stage III colon or rectal cancer, patients were randomized to undergo observation or receive anti-17-1A antibody after surgical resection.
36,37 A decrease in mortality of 32% and relapse rate of 23% was identified. Although this is comparable to the benefit seen with adjuvant 5-FU and levamisole, the study has been criticized for its small sample size and inclusion of rectal primary cancers. 38 In a European study, 2761 patients with stage III colon cancer were randomized to receive anti-17-1A with 5-FU and leucovorin, 5-FU and leucovorin alone, or anti-17-1A antibody alone. 39 No benefit was seen with the addition of anti-17-1A to 5-FU and leucovorin, and the use of anti-17-1A monotherapy was associated with a shorter overall survival and diseasefree survival compared with 5-FU and leucovorin (70.1% compared with 76.1% and 53.0% compared with 65.5%, respectively).
Results from the comparable North and South American study, with 1839 patients enrolled, were recently reported. 40 Patients with stage III colon cancer randomized to receive anti-17-1A with 5-FU and leucovorin as adjuvant therapy had a 3-year overall survival of 81.6% compared with 78.9% for the group receiving chemotherapy alone (P = .023). No increase in toxicity was observed with the addition of 17-1A. An Intergroup study with stage II colon cancer patients receiving either standard follow-up care or anti-17-1A has been completed, the results from which are not yet available. Other monoclonal antibodies in development include the anti-ideotype antibody, CeaVac, directed against carcinoembryonic antigen.
41 Administration of CeaVac by monthly injection resulted in high-titer humoral responses when used alone for metastatic CRC, 42 as well as when used as adjuvant chemotherapy for resected CRC. 41 Phase III trials are currently in development for patients with resected CRC.
Molecular Targeted Therapy
New approaches in the treatment of CRC have focused on the use of molecular targeted therapy. The molecular changes that occur in the progression of CRC have been meticulously identified. The epidermal growth factor receptor (EGFR) is a tyrosine kinase that regulates tumor cell division, repair, and survival and is involved in tumor metastasis. Many human cancers express or overexpress the receptor.
43,44
Expression of EGFR has been shown to be associated with a poor prognosis and an increased risk of metastases in CRC. 45, 46 Agents that inhibit EGFR may impact growth or progression of EGFR-expressing tumors.
Inhibition of EGFR activity can be achieved by blocking the receptor with an anti-EGFR monoclonal antibody or by inhibiting the tyrosine kinase activity. A phase II study evaluated the activity of the chimeric monoclonal antibody cetuximab (IMC-C225) in irinotecan-refractory colorectal tumors. 47 In this study, 151 patients with CRC refractory to 5-FU and irinotecan, and whose tumors expressed EGFR, were treated with cetuximab and irinotecan. A partial response rate of 22.5% was achieved in this study. The authors concluded that cetuximab can produce major objective responses in irinotecan-refractory tumors, but the documentation of irinotecan resistance is being questioned.
Early results from a phase II study of single agent cetuximab were recently reported. 48 Fifty-seven patients with advanced CRC that had progressed on 5-FU and irinotecan regimens and whose tumors expressed EGFR were treated with cetuximab as a single agent. Partial responses were seen in 6 patients (10.5%), and stable disease was maintained in 21 (36.8%), demonstrating activity of this drug as a single agent and setting the stage for further development. Trials incorporating cetuximab into first-line therapy with standard chemotherapy are in development. ABX-EGF is a fully human monoclonal antibody directed against the EGFR that has demonstrated EGFR blockade with a tolerable safety profile in phase I pharmacokinetic and safety studies. 49, 50 Further development of this agent is ongoing.
The activity of tyrosine kinase inhibitors is also being evaluated in CRC. ZD1839 (Iressa) is a selective potent inhibitor of EGFR tyrosine kinase. Activity has been demonstrated without significant increase in toxicity for patients receiving ZD1839 with 5-FU and leucovorin for advanced CRC. 51 The activity of ZD1839 as a single agent in chemotherapy refractory disease was recently evaluated by ECOG. The results of these studies and correlation with EGFR expression remain to be quantified. Ongoing studies are evaluating the effect of adding ZD1839 to combination chemotherapy regimens.
OSI-774 is another potent selective EGFR tyrosine kinase inhibitor. In a phase I pharmacologic study that included 9 patients with previously treated CRC, 3 patients experience response or disease stabilization. 52 Again, further studies with this compound in combination with chemotherapy are planned.
Angiogenesis Inhibition
Inhibition of angiogenesis is another area of active research. Researchers have shown that the expression of vascular endothelial growth factor (VEGF) increases with progression from adenoma to CRC and is associated with a stage-dependent decrease in survival. 53 Bevacizumab (rhuMab VEGF) is a recombinant human monoclonal antibody (rhuMab) directed against the VEGF receptor. A randomized phase II study evaluated the addition of low-dose bevacizumab (ld rhuMAb VEGF) or high-dose bevacizumab (hd rhuMAb VEGF) to 5-FU and leucovorin on the Roswell Park regimen in 104 patients with advanced CRC. 54, 55 The addition of ld rhuMAb VEGF compared with 5-FU and leucovorin alone resulted in a statistically significant increase in response rate (40% vs 17%; P = .03) and time to disease progression (9 vs 5.2 months; P = .005). Preliminary survival analysis revealed an improvement in survival, with a median survival of more than 17.3 months with the addition of ld rhuMAb as compared with 13.8 months (P = .03). The addition of hd rhuMAb to 5-FU and leucovorin did not result in significant differences in response rate, time to disease progression, or survival for unclear reasons. A phase II study conducted by ECOG of bevacizumab and the bolus regimen of 5-FU, leucovorin, and irinotecan as first-line therapy for advanced CRC has completed accrual with acceptable toxicity. Results of a randomized phase III trial are pending. A phase III study of infusion and bolus 5-FU and oxaliplatin with or without bevacizumab as second-line therapy in advanced CRC is ongoing in ECOG.
The tyrosine kinase inhibitor SU5416 inhibits phosphorylation of the VEGF receptor and its subsequent activation. It has been used in clinical trials as a single agent; 56 with 5-FU and leucovorin; 57 and with 5-FU, leucovorin, and irinotecan. 58 Recently, a planned interim efficacy and safety analysis of a phase III study of standard chemotherapy with or without SU5416 revealed a lack of clinical benefit with the addition of the angiogenesis inhibitor. 59 Based on these findings, the CRC clinical trial program has been closed.
Cyclo-oxygenase-2 (COX-2) is an enzyme that converts arachidonic acid to prostaglandins. It is overexpressed in 80% to 90% of CRC and plays a role in tumorigenesis and metastasis. 60 Inhibition of COX-2 with celecoxib has demonstrated activity in colorectal tumorigenesis in various models 60, 61 and to decrease the number and size of colon polyps in patients with familial adenomatous polyposis. 62 The addition of celecoxib may also decrease the incidence of prostaglandinmediated toxicity of cytotoxic therapy. An ongoing phase II study included the addition of celecoxib to the IFL regimen, 63 without evidence of increased toxicity. A retrospective analysis of patients taking capecitabine with or without celecoxib revealed improvement in the side-effect profile. 64 Prospective studies are ongoing and planned to define further the role of COX-2 inhibitors in the treatment of CRC. The European VICTOR (Vioxx in Colorectal Cancer Therapy: Definition in Optimal Regime) trial will explore the role of the COX-2 inhibitor rofecoxib after adjuvant chemotherapy for patients with resected CRC.
Conclusions
The past 5 years have seen exciting developments in the treatment of CRC ( Table 5 ). The addition of new active chemotherapy agents has led to combination chemotherapy regimens that improve survival in advanced CRC. Second-line therapy for patients whose tumors progressed while they were on first line is now available and clearly has been shown to result in further benefit. Ongoing studies will help to determine the most beneficial combination and sequence of agents. The identification and development of targeted drugs may themselves be effective or enhance the cytotoxic effects of chemotherapy without added toxicity. Only through well-designed clinical trials will the benefit of these new agents be defined and outcomes improved.
